This study aimed to examine the effectiveness of two TrxR1 inhibitors, auranofin and [Au(d2pype)2]Cl, on overcoming intrinsic imatinib resistance in CML and to investigate the possible links between the CML causing protein, bcr-abl, and the Trx system. The gene discussed is TXNRD1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.